Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
C4 Therapeutics Inc. currently manages 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 4 distinct art units, indicating a moderate level of specialization in its patent filings. The prosecution workload involves 5 distinct examiners, which suggests that each pending matter is being handled by a different individual.
HEITMEIER, KENDALL NICOLE is identified as the busiest examiner for this portfolio, currently overseeing 1 pending office action. This distribution among 5 distinct examiners means that no single examiner holds a concentrated portion of the company's active cases. The presence of 4 distinct art units for these 5 actions reflects a focused but slightly varied technical scope within the broader biotechnology sector.
For practitioners, the 1 to 1 ratio of pending office actions to distinct examiners suggests a fragmented prosecution landscape. With 5 distinct examiners involved, the company must navigate 5 different sets of examiner preferences and styles. The concentration of 5 pending office actions within 4 distinct art units further implies that while the technology is specialized, it touches upon several specific technical classifications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting only | 2 (50%) |
| Double-patenting + other | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
| HASTINGS, ALISON AZAR | 1 | 62.5% | +42.1% |
| AULAKH, CHARANJIT | 1 | 80.7% | -14.5% |
| ELENISTE, PIERRE PAUL | 1 | 35.4% | +31.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18534395 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | AULAKH, CHARANJIT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18516589 | EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS | ELENISTE, PIERRE PAUL | 14d |
| 18576933 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | HASTINGS, ALISON AZAR | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1627 | 1 |
| 1621 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18774801 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | SHIAO, REI TSANG | 1691 | §112DP | Non-Final OA | — | Pending | Jul 16, 2024 |
| 18576933 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | HASTINGS, ALISON AZAR | 1627 | §103 | Final Rejection | — | Pending | Jan 05, 2024 |
| 18534395 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | AULAKH, CHARANJIT | 1621 | DP | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18516589 | EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS | ELENISTE, PIERRE PAUL | 1622 | DP | Final Rejection | 14d | Pending | Nov 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialC4 Therapeutics Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Rei Tsang Shiao has the most, with 1 of C4 Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
